ophthalmology

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

England poised to roll out drug for rare eye disease LHON

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

News

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.

News

Boehringer raises hope of oral drug for diabetic eye disease

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

News

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

News

SpliceBio chief executive Miquel Vila-Perelló

SpliceBio gathers $135m for eye disease gene therapies

Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.

Nicox plans filings for glaucoma after phase 3 win

England poised to roll out drug for rare eye disease LHON

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Boehringer raises hope of oral drug for diabetic eye disease

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

SpliceBio gathers $135m for eye disease gene therapies

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

ophthalmology

Editor's Picks